

Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity

Elisa Giacomini,^{†,‡} Angela Nebbioso,[§] Alfonso Ciotta,[§] Cristina Ianni,[†] Federico Falchi,^{†,‡} Marinella Roberti,^{*,†} Manlio Tolomeo,^{||} Stefania Grimaudo,[⊥] Antonietta Di Cristina,[⊥] Rosaria Maria Pipitone,[⊥] Lucia Altucci,^{§,#} and Maurizio Recanatini[†]

[†]Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy

[‡]Department of Drug Discovery and Development, Italian Institute of Technology, Via Morego 30, 16163 Genova, Italy

[§]Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Vico L. De Crecchio 7, 80138 Naples, Italy

^{||}Interdepartmental Center of Research in Clinical Oncology and Department of Infectious Diseases, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy


[⊥]DiBiMIS, Laboratory of Molecular Pathology, Institute of Gastroenterology, University of Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy

[#]Institute of Genetics and Biophysics, IGB, Via Pietro Castellino 111, 80131 Naples, Italy

Supporting Information

ABSTRACT: Given our interest in finding potential antitumor agents and in view of the multifactorial mechanistic nature of cancer, in the present work, taking advantage of the multifunctional ligands approach, new chimeric molecules were designed and synthesized by combining in single chemical entities structural features of SAHA, targeting histone deacetylases (HDACs), with substituted stilbene or terphenyl derivatives previously obtained by us and endowed with antiproliferative and pro-apoptotic activity. The new chimeric derivatives were characterized with respect to their cytotoxic activity and their effects on cell cycle progression on different tumor cell lines, as well as their HDACs inhibition. Among the other, *trans-6* showed the most interesting biological profile, as it exhibited a strong pro-apoptotic activity in tumor cell lines in comparison with both of its parent compounds and a marked HDAC inhibition.

KEYWORDS: Multifunctional ligands, chimeric compound, stilbene, HDAC inhibition, antiproliferative activity



To address the biological complexity of cancer¹ and to develop adequate therapeutic tools, an interesting and fruitful strategy is provided by the development of “multiple ligands”, rationally designed single chemical entities able to modulate multiple altered pathways, overcoming problems like different pharmacokinetics and poor compliance.^{2–4} In the present report, we applied this paradigm to develop novel multifunctional ligands able to interfere with different molecular pathways involved in neoplastic diseases, specifically targeting some control mechanisms of epigenetics^{5,6} and cell cycle progression.

Histone deacetylase inhibitors (HDIs)^{7,8} have emerged as a new class of promising cancer therapeutic agents and their synergistic effects with many other drugs are well documented.^{9,10} Several HDIs belonging to different chemical classes¹¹ are currently in clinical trials as monotherapy or in combination with chemo- or radiation therapy.¹² According to the well-known pharmacophore model for HDIs,^{13,14} a deacetylase inhibitor should bear a CAP group to interact with the rim of the catalytic tunnel of the enzyme, a connection

unit, linking the CAP to a hydrophobic spacer and lying into the tunnel, and an enzyme inhibiting group, able to complex the zinc ion, crucial for the catalysis at the bottom of the tunnel. SAHA (suberoylanilide hydroxamic acid, Vorinostat, Zolinza) (Figure 1A) was the first HDI approved by FDA (in 2006) for the treatment of the rare cancer cutaneous T-cell lymphoma (CTCL).⁸

On the other side, because of our ongoing interest in finding new anticancer agents, we recently synthesized small libraries of stilbenes and terphenyls (privileged structures)^{15–17} (Figure 1B) able to induce apoptosis and differentiation in leukemia cells, after arresting the cell cycle in G₀–G₁ phase.^{18–20} Agents that are able to block and/or kill cancer cells in G₀–G₁ phase are currently considered of interest because most chemotherapeutic drugs available for the treatment of malignancies act in the S or G₂–M phase of the cell cycle, but not in G₀–G₁,

Received: March 4, 2014

Accepted: July 7, 2014

Published: July 8, 2014




Figure 1. (A) SAHA. (B) Representative terphenyl and stilbene derivatives endowed with pro-apoptotic or differentiating activity.

thus allowing a variable percentage of cells in G_0 – G_1 phase to escape from the cytotoxic effects of the therapy.










On the basis of these premises, following the multifunctional ligands approach, we designed and synthesized novel chimeric compounds as potential antitumor agents, by incorporating the linker- Zn^{2+} -binding motif fragment of SAHA into the selected most biologically promising terphenyl **1**¹⁹ or stilbenes *cis*-**2** and *trans*-**2**¹⁸ (Figure 1B). A new generation of more powerful HDAC inhibitors could represent an opportunity for a clinical use as single agent, unlike what happens now where the HDAC inhibitors are mainly used in combination with other cytotoxic agents.²¹

According to Morphy and Rankovic,^{2,3} the new chimeric compounds **3**, **4**, *cis*-**6**, and *trans*-**6** (Table 1) were “designed in” by linking together the appropriate fragments via a suitable connection unit, while a “merged” approach was applied for chimeric compound **5** in which the selected frameworks were integrated and overlapped in a common structure (Figure S1, Supporting Information). The new derivatives were then characterized with respect to their cytotoxic activity and their effects on cell cycle progression and epigenetics on leukemia Bcr-Abl-expressing K562, monoblastic U937, and breast cancer MCF-7 cell line.

The desired chimeric compounds were synthesized as described in the following. The synthetic strategy for compounds **3** and **4** bearing a terphenyl fragment first consisted of a PyBOP coupling between protected terphenyl acid **7** and the appropriate amino methyl esters **8** and **9**. The resulting amides **10** and **11** were deprotected by tetrabutylammonium fluoride (TBAF) giving **12** and **13**, which reacted with hydroxylamine hydrochloride in the presence of sodium methoxide as a base to obtain the hydroxamic acid functions, affording the final compounds **3** and **4**, respectively (Scheme 1). Similarly, deprotection with TBAF of the terphenyl methyl ester **14** gave the dihydroxy derivative **15**, which was treated with hydroxylamine hydrochloride in the same conditions described above to give the desired compound **5** (Scheme 2). Chimeric compounds *cis*-**6** and *trans*-**6** possessing the stilbene fragment were prepared through amidation by use of DCC as coupling reagent between suberic acid monomethyl ester (commercially available) **16** and the aminostilbenes *cis*-**2** and *trans*-**2**¹⁸ to obtain amides *cis*-**17** and *trans*-**17**, respectively. Conversion of the methyl ester to the hydroxamic acid moiety afforded hybrid compounds *cis*-**6** and *trans*-**6** (Scheme 3). Synthetic strategies for intermediates **7** and **14** (Scheme S1) and **8** and **9** (Scheme S2) are given in the Supporting Information.


Initially, we investigated the antiproliferative and the proapoptotic activities of chimeric derivatives **3**, **4**, **5**, *cis*-**6** and *trans*-**6** in comparison with their parent compounds SAHA, **1**, *cis*-**2**, and *trans*-**2** on K562 cells (Table 1).

Table 1. IC_{50} ($\mu M \pm SE$) and AC_{50} ($\mu M \pm SE$) of **3**, **4**, **5**, *cis*-**6**, and *trans*-**6** and Their Parent Compounds SAHA, **1**, *cis*-**2**, and *trans*-**2** Evaluated in K562 Cells after 48 h of Treatment


Compounds	IC_{50}^a	AC_{50}^b
 SAHA	1 ± 0.2	10 ± 1.4
 1	20 ± 2.3	> 50
 Trans-2	2.5 ± 0.4	20 ± 4.3
 Cis-2	0.025 ± 0.006	0.25 ± 0.03
 3	2.5 ± 0.5	16 ± 2.5
 4	6 ± 0.3	38 ± 6.4
 5	20 ± 6.2	> 50
 Trans-6	0.7 ± 0.009	5 ± 0.6
 Cis-6	7.5 ± 0.5	40 ± 8.2

^aConcentration (μM) able to inhibit 50% cell growth. ^bConcentration able to induce apoptosis in 50% of cells. All points were tested in triplicate with error bars indicating the standard deviation.


The antiproliferative activity of each compound was evaluated by counting cells with an automatic cell counter; apoptosis was evaluated by annexin V test. The effects of chimeric compounds on K562 cell cycle progression were evaluated by flow cytometry after staining cells with propidium iodide, and they were compared to the effects of the parent compounds alone or in association (Figure S2, Supporting Information). Among the chimeric hydroxamates **3**–**5** bearing the terphenyl fragment, compound **3** containing the six methylenes motif of SAHA exhibited an increased cytotoxic

Scheme 1^a

^aReagents and conditions: (a) PyBop, DIEA, CH₂Cl₂, 72h rt; (b) 1 M TBAF, 2 h 0 °C to rt; (c) NH₂OH·HCl, NaOMe 30%, MeOH, 24 h, 0 °C to rt.

Scheme 2^a

^aReagents and conditions: (a) 1 M TBAF, 2 h 0 °C to rt; (b) NH₂OH·HCl, NaOMe 30%, MeOH, 24 h, 0 °C to rt.

Scheme 3^a

^aReagents and conditions: (a) HOBt, DCC, DMF, 48 h, rt; (b) NH₂OH·HCl, NaOMe 30%, MeOH, 3 h, 0 °C to rt.

and proapoptotic activity with respect to the parent compound **1** (IC₅₀, 2.5 μM vs 20 μM; AC₅₀, 16 μM vs >50 μM, respectively, Table 1), while it was less potent than SAHA. Reducing the alkyl chain to five methylenes as in **4** resulted in a decrease of activity even though still higher if compared to **1**, while compound **5** lacking the methylene chain displayed the same activity as parent terphenyl **1**. These results suggested that the alkyl hydroxamic chain conferred a better cytotoxic and proapoptotic activity to the terphenyl scaffold.

Unfortunately the cell cycle analysis (Figure S2, Supporting Information) revealed that none of the chimeric compounds

3–5 was able to selectively block cells in G₁ phase as **1** or the **1** and SAHA combination as we expected. Interesting results were obtained with *trans-6* and *cis-6*, designed by combining the structural features of SAHA and two stilbenes, *trans-2* and *cis-2*, respectively, previously designed by us and endowed with potent pro-apoptotic activity (Table 1).¹⁸ The cytotoxic activity of hydroxamate *cis-6* was markedly lower than that of parents *cis-2* and SAHA (Table 1). Noteworthy, *trans-6* (IC₅₀, 0.7 μM; AC₅₀, 5.0 μM) was more potent as cytotoxic agent than *trans-2* (IC₅₀, 2.5 μM; AC₅₀, 20 μM) and SAHA (IC₅₀, 1 μM; AC₅₀, 10 μM). In particular, the ability to induce apoptosis in K562 cells was two times higher than that observed with SAHA (Table 1). The pattern of cell cycle distribution of K562 cells after exposure to *trans-6* and *cis-6* showed that both compounds behaved similarly to SAHA (block in G₁ and G₂–M phases) and differently from the parent compounds alone (block in G₂–M) or in combination (prevalent block in G₁), thus suggesting they could share a mechanism of action similar to that of SAHA (Figure S2, Supporting Information).

Because of its interesting cytotoxic activity on K562 cells, we considered *trans-6* the best candidate for further investigations. First, we studied this compound in two different cell lines: the monoblastic U937 and the breast cancer MCF-7 cells. Once again, *trans-6* resulted to act similarly to SAHA as it was able to induce a G₁- and G₂-block in U937 and MCF-7 cells, respectively, with progressive cell death (Figure S3A,B, Supporting Information). To better understand the progressive cell death induction, a cytofluorimetric analysis was performed to discriminate necrosis from apoptosis. As shown in Figure 2, *trans-6*, similarly to SAHA, triggered an apoptotic death, but with a 2-fold increase. These data corroborated and extended the value of the AC₅₀ shown in Table 1.




Figure 2. Left: apoptosis/necrosis evaluation, by Annexin V/PI doubling staining by flow cytometric assays on U937 cells treated with 5 μM *trans-6* or SAHA (taken as positive control) for 48 h. All points were tested in triplicate with error bars indicating the standard deviation. Right: Western blot for caspase 8 after a stimulation of 24 h for U937 cells and 48 h for MCF-7 cells; compounds were used at concentration of 5 μM. ImageJ was used to quantify protein expression levels. The ERKs signal accounts for equal loading.

To test HDAC inhibitory potential of all new chimeric compounds, enzymatic assays were performed against human recombinant (hr) enzymes (Table 2 and Figure S4A, Supporting Information). Among the terphenyl derivatives, the compound **4**, containing the five methylene chain, although exhibited an interesting inhibitory activity against hrHDAC1 (IC₅₀, 0.9 μM), was completely inactive on hrHDAC4 as **3** and **5**, demonstrating that the terphenyl scaffold is not a suitable moiety for the anti-HDAC activity. At the same time the

Table 2. Human Recombinant HDAC1 Inhibitory Activity of Compounds 3–5, Compared with SAHA and Human Recombinant HDAC4 and HDAC6 Inhibitory Activity of *trans*-6, *cis*-6, and SAHA

compounds	inhibition at 5 μ M (% \pm SE) ^a			IC ₅₀ (μ M) (95% confidence interval)		
	hrHDAC1	hrHDAC4	hrHDAC6	hrHDAC1	hrHDAC4	hrHDAC6
SAHA	68.9 \pm 1.73	21.5 \pm 0.25	40.7 \pm 0.84	0.6 (0.313–3.224)	7.8 (5.88–12.06)	5.6 (5.31–7.45)
3	20.4 \pm 2.12	0	n.d. ^b	15.7 (7.675–32.13)	n.d. ^b	n.d. ^b
4	62.1 \pm 1.87	0	n.d. ^b	0.9 (0.6941–1.088)	n.d. ^b	n.d. ^b
5	33.1 \pm 2.86	0	n.d. ^b	8.9 (6.496–12.34)	n.d. ^b	n.d. ^b
<i>trans</i> -6	91.7 \pm 1.19	39.1 \pm 0.78	50.2 \pm 1.40	0.8 (0.493–1.163)	9.8 (6.24–15.54)	1.3 (0.437–3.851)
<i>cis</i> -6	88.3 \pm 2.0	68.1 \pm 1.3	74.7 \pm 2.0	2.1 (1.207–3.614)	7.6 (4.37–13.34)	1.6 (0.512–5.049)

^aAll points were tested in triplicate with error bars indicating the standard deviation. ^bNot determined.

stilbene hydroxamate *trans*-6 and its *cis* isoform, *cis*-6, resulted in being strong HDAC1 inhibitors (IC₅₀, 0.8 and 2.1 μ M, respectively), and their effect was therefore tested on HDAC4 and 6 (Table 2 and Figure S4B, Supporting Information). Both compounds at 5 μ M were also able to inhibit these two enzymes better than SAHA showing good IC₅₀ values (IC₅₀, 9.8 and 7.6 μ M for HDAC4 and 1.3 and 1.6 μ M for HDAC6, respectively). In particular, *trans*-6 privileged HDAC1 inhibition. However, *cis*-6 inhibited all tested enzymes at comparable levels (Figure S4, Supporting Information).

Given the above results, again we considered *trans*-6 the best candidate for further investigations. According to its HDAC inhibitory action, *trans*-6 showed the ability to induce a high histone hyper-acetylation in both U937 and MCF-7 cell lines (Figure 3). Western blotting analyses showed a hyper-




Figure 3. Western blot analyses carried out for the indicated targets in U937 and MCF-7 cells after 24 h of treatment. ImageJ was used to quantify protein expression. Histone H1, H4, and ERKs indicate equal loading. SAHA and *trans*-6 were used at concentration of 5 μ M.

acetylation of histone H3 in lysines 9 and 14 (H3K9 and 14ac) and of histone H4 in lysine 16 (H4K16ac). Remarkably, the quantification of the signals showed a 6-fold against a 4-fold increase of acetylation of histone H3 for *trans*-6 compared to its parent compound SAHA, respectively. Taken together, these results demonstrated that *trans*-6 was able to increase acetylation of lysine residues on the N-terminal histones tails of H3 and H4. Furthermore, *trans*-6 was also able to trigger a repair pathway, causing the acetylation in lysine 382 of p53 (p53K382ac) and up-regulating the cell-cycle inhibitor p21^{waf1/cip1} (Figure 3). As HDAC6 assay showed, *trans*-6, as a

HDAC6 inhibitor, induced a clear increment of the acetylation level of the α -tubulin (Figure 3).

To better address the anticancer activity of *trans*-6, proliferation and migration analysis were also performed in MCF-7 cells in real-time mode. The inhibitory effects of *trans*-6 on the proliferation were showed within the 36 h of treatment and were already evident in the early phases after 10 h (Figure 4). This trend was highlighted by the doubling time analysis,




Figure 4. (A) Proliferation analysis in real time of MCF-7 cells treated with 5 μ M SAHA or *trans*-6 as CI (cell index) vs time (left) within 36 h and as doubling time (right) within the interval 10–18 h. (B) Migration analysis in real-time of MCF-7 cells treated with 5 μ M *trans*-6 as CI vs time (left) within 27 h and as slope within 24 h.

which showed a strong decrease of this parameter both for *trans*-6 and SAHA within the interval 10–18 h (Figure 3A). Migration analyses showed a clear ability of *trans*-6 to inhibit the tumor cell migration. The effects were more evident if represented in slope values displaying a decrease of 25% within 24 h (Figure 4B).

On the basis of these results, it appears that the chimeric hydroxamates bearing the terphenyl motif did not enhance the biological activity of the parent compounds, losing the peculiar block in G₁ phase and showing a not significant HDAC inhibitory profile. However, the stilbene structure proved to be a valid scaffold for the design of strong HDAC inhibitors. Of interest, the *trans* configuration of the stilbene architecture

seems to be an important feature in conferring a slight selectivity toward the different isoforms of HDACs.

In continuation of our research for innovative antitumor lead candidates, we designed and synthesized some chimeric compounds following the multifunctional ligands approach. Even though the new molecules did not show a pharmacologically chimeric behavior, *trans-6*, obtained combining the structural features of SAHA and a stilbene derivative previously designed by us, was able to induce a stronger apoptosis in K562, U937 and MCF-7 cells than both the parent compounds. Moreover, it showed a marked HDAC inhibitory action and a clear ability to inhibit the tumor cell migration. Our strategy contributed to explore the chemical space around SAHA, proving the stilbene structure as a valuable CAP group in HDAC pharmacophore. Therefore, *trans-6* could be considered a suitable lead structure to develop new agents endowed with a promising anticancer potential. Noteworthy, from a medicinal chemistry point of view, the stilbene scaffold is a privileged structure in which the biological relevance meets the synthetic accessibility, allowing to rapidly obtain variously substituted analogues, making the follow-up studies of the identified hits more efficient.

EXPERIMENTAL METHODS

Chemistry. General Chemical Methods. Reaction progress was monitored by TLC on precoated silica gel plates (Kieselgel 60 F₂₅₄ Merck) and visualized by UV254 light; hydroxamates were viewed by staining with FeCl₃ 5% aqueous solution. Flash column chromatography was performed on silica gel (particle size 40–63 μM, Merck). When needed, silica was demetallated by suspending and standing overnight in concentrated HCl, filtered and washed several times with Et₂O until free of chloride ions, and dried for 48 h at 120 °C. All solvents were distilled prior to use. All reagents were obtained from commercial sources and used without further purification. Unless otherwise stated, all reactions were carried out under an inert atmosphere. Compounds were named relying on the naming algorithm developed by CambridgeSoft Corporation and used in Chem-BioDraw Ultra 11.0. ¹H NMR and ¹³C NMR spectra were recorded on Varian Gemini at 400 and 100 MHz, respectively. Chemical shifts (δ_H) are reported relative to TMS as internal standard. Mass spectrum was recorded on a V.G. 7070E spectrometer or on a Waters ZQ 4000 apparatus operating in electrospray (ES) mode. Purity of compounds was determined by elemental analyses; purity for all the tested compounds was ≥95% (see Supporting Information).

General Procedure for Chimeric Compounds 3–5, cis-6, and trans-6. To cooled solutions of the appropriate methyl esters **12**, **13**, **19**, *cis-20*, and *trans-20* (1 equiv) in MeOH/THF 2/1 (5 mL), hydroxylamine hydrochloride NH₂OH·HCl (10 equiv) and sodium methylate solution 30% in MeOH (12.4 equiv) were added. The reaction mixture was stirred for 3 to 24 h at room temperature then cooled in an ice bath and acidified with 6 N HCl to pH 4. Water was added to dissolve the salt, and the mixture was concentrated *in vacuo* to remove MeOH/THF. The aqueous phase was extracted with EtOAc (3 × 10 mL) and purified by flash chromatography on demetallated silica gel.

(trans)-N1-(5-(3,5-Dimethoxystyryl)-2-methoxyphenyl)-N8-hydroxyoctanediamide (trans-6). Derivative *trans-17* (0.17 g, 0.37 mmol) was allowed to react according to the general procedure. The reaction mixture was stirred for 3 h at room temperature. After the workup, the precipitated product was filtered and washed with Et₂O to yield *trans-6* (0.11 g, yield 64%) as white powder. ¹H NMR (400 MHz, CD₃OD) δ 1.38–1.39 (m, 4H), 1.60–1.64 (m, 2H), 1.70 (t, J = 7.2, 2H), 2.06–2.10 (m, 2H), 2.41–2.44 (m, 2H), 3.78 (s, 6H), 3.87 (s, 3H), 6.34–6.35 (m, 1H), 6.65 (d, J = 2.4 Hz, 2H), 6.94–6.98 (m, 2H), 7.02–7.06 (m, 1H), 7.24–7.25 (m, 1H), 8.18 (d, J = 1.6 Hz, 1H) ppm; ¹³C NMR (100 MHz, CD₃OD) δ 26.6, 26.7, 29.8, 33.7, 37.7,

55.7, 56.4, 100.6, 105.3, 111.9, 121.1, 124.9, 128.2, 128.4, 129.7, 131.3, 140.9, 141.0, 151.3, 162.5, 174.7 ppm; MS (ES) *m/z* 479 [M + Na]⁺.

ASSOCIATED CONTENT

Supporting Information

Spectroscopic data for final compounds **3–5** and *cis-6*, and synthesis and characterization of compounds **7–15** and *cis-* and *trans-17*, elemental analyses, detailed biological protocols; Schemes S1 and S2, Table S1, and Figures S1–S4. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*(M.Ro.) E-mail: marinella.roborti@unibo.it. Phone: +(39) 051 2099738.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by a PRIN2009 and PRIN2012 Grant from MiUR, Italy; EU: the Blueprint (contract no. 282510), Epigenomics Flagship Project EPIGEN (MIUR-CNR); and the Italian Association for Cancer Research (AIRC no. 11812).

REFERENCES

- (1) Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **2011**, *144*, 646–674.
- (2) Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. *Drug Discovery Today* **2004**, *9*, 641–651.
- (3) Morphy, R.; Rankovic, Z. Designing multiple ligands: medicinal chemistry strategies and challenges. *Curr. Pharm. Des.* **2009**, *15*, 587–600.
- (4) Peters, J. U. Polypharmacology: foe or friend? *J. Med. Chem.* **2013**, *56*, 8955–8971.
- (5) Nebbioso, A.; Pereira, R.; Khanwalkar, H.; Matarese, F.; Garcia-Rodriguez, J.; Miceli, M.; Logie, C.; Keding, V.; Ferrara, F.; Stunnenberg, H. G.; De Lera, A. R.; Gronemeyer, H.; Altucci, L. Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. *Mol. Cancer Ther.* **2011**, *10*, 2394–2404.
- (6) Conte, M.; Altucci, L. Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. *Clin. Cancer Res.* **2012**, *18*, 5526–5534.
- (7) Barneda-Zahonero, B.; Parra, M. Histone deacetylases and cancer. *Mol. Oncol.* **2012**, *6*, 579–589.
- (8) Ververis, K.; Hiong, A.; Karagiannis, T. C.; Licciardi, P. V. Histone deacetylase inhibitors (HDACi): multitargeted anticancer agents. *Biol. Targets Ther.* **2013**, *7*, 47–60.
- (9) Carew, J. S.; Giles, F. J.; Nawrocki, S. T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. *Cancer Lett.* **2008**, *269*, 7–17.
- (10) Ai, T.; Cui, H.; Chen, L. Multi-targeted histone deacetylase inhibitors in cancer therapy. *Curr. Med. Chem.* **2012**, *19*, 475–487.
- (11) Carafa, V.; Miceli, M.; Altucci, L.; Nebbioso, A. Histone deacetylase inhibitors: a patent review (2009–2011). *Expert Opin. Ther. Pat.* **2013**, *23*, 1–17.
- (12) Benedetti, R.; Conte, M.; Altucci, L. Targeting HDACs in diseases: where are we? *Antioxid. Redox Signaling* **2014**, DOI: 10.1089/ars.2013.5776.
- (13) Mai, A.; Massa, S.; Rotili, D.; Cerbara, I.; Valente, S.; Pezzi, R.; Simeoni, S.; Ragno, R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. *Med. Res. Rev.* **2005**, *25*, 261–309.
- (14) Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors. *J. Med. Chem.* **2003**, *46*, 5097–5116.

(15) Liu, J. K. Natural terphenyls: developments since 1877. *Chem. Rev.* **2006**, *106*, 2209–2223.

(16) Yin, H.; Hamilton, A. D. Strategies for targeting protein–protein interactions with synthetic agents. *Angew. Chem., Int. Ed. Engl.* **2005**, *44*, 4130–4163.

(17) Davis, J. M.; Tsou, L. K.; Hamilton, A. D. Synthetic non-peptide mimetics of alpha-helices. *Chem. Soc. Rev.* **2007**, *36*, 326–334.

(18) Roberti, M.; Pizzirani, D.; Simoni, D.; Rondanin, R.; Baruchello, R.; Bonora, C.; Buscemi, F.; Grimaudo, S.; Tolomeo, M. Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. *J. Med. Chem.* **2003**, *46*, 3546–3554.

(19) Roberti, M.; Pizzirani, D.; Recanatini, M.; Simoni, D.; Grimaudo, S.; Di Cristina, A.; Abbadessa, V.; Gebbia, N.; Tolomeo, M. Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. *J. Med. Chem.* **2006**, *49*, 3012–3018.

(20) Pizzirani, D.; Roberti, M.; Cavalli, A.; Grimaudo, S.; Di Cristina, A.; Pipitone, R. M.; Gebbia, N.; Tolomeo, M.; Recanatini, M. Antiproliferative agents that interfere with the cell cycle at the G1 → S transition: further development and characterization of a small library of stilbene-derived compounds. *ChemMedChem* **2008**, *3*, 345–355.

(21) Taddei, M.; Cini, E.; Giannotti, L.; Giannini, G.; Battistuzzi, G.; Vignola, D.; Vesci, L.; Cabri, W. Lactam based 7-amino suberoylamide hydroxamic acids as potent HDAC inhibitors. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 61–64.